Literature DB >> 16891039

Antibiotic use in two cohorts of German intensive care units.

K de With1, E Meyer, M Steib-Bauert, F Schwab, F D Daschner, W V Kern.   

Abstract

Antibiotic use was evaluated in two cohorts of intensive care units (ICUs) in Germany. One cohort included ICUs participating in a surveillance programme (N=34) collecting antibiotic use and bacterial resistance data, with quarterly feedback. The second ICU cohort was from a cross-sectional study and represented a sample from hospitals in South-west Germany (N=58). Two dose definitions were used. These were the World Health Organization/Anatomical Therapeutic Chemical Classification (ATC) 2001 definition of defined daily dose (DDD), and a definition of recommended daily dose (RDD) that better reflected the currently prescribed dosages of parenteral drugs for hospitalized patients. Data were expressed as DDD or RDD per 100 patient-days. It was determined whether hospital size and affiliation, year of study and ICU type had an influence on overall use of antibiotics. Overall use differed between the two ICU cohorts irrespective of the dose definitions used. High use of antibiotics was primarily associated with hospital affiliation (university vs non-university) and hospital size. Mean overall use of antibiotics in non-university hospital ICUs ranged between 106 and 111 DDD/100 (59 and 67 RDD/100) for different hospital size categories, compared with 140 DDD/100 (87 RDD/100) in university hospital ICUs. In conclusion, in order to compare the use of antibiotics between ICU cohorts and to assess trends over time, data adjustment is required for hospital affiliation and size.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891039     DOI: 10.1016/j.jhin.2006.05.018

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  8 in total

1.  Deriving measures of intensive care unit antimicrobial use from computerized pharmacy data: methods, validation, and overcoming barriers.

Authors:  David N Schwartz; R Scott Evans; Bernard C Camins; Yosef M Khan; James F Lloyd; Nadine Shehab; Kurt Stevenson
Journal:  Infect Control Hosp Epidemiol       Date:  2011-05       Impact factor: 3.254

2.  Complicated community-acquired soft tissue infection by MRSA from porcine origin.

Authors:  Ph Declercq; D Petré; B Gordts; A Voss
Journal:  Infection       Date:  2007-10-31       Impact factor: 3.553

3.  Hospital antibiotic management in Germany--results of the ABS maturity survey of the ABS International group.

Authors:  Winfried V Kern; Michaela Steib-Bauert; Steffen Amann; Matthias Fellhauer; Katja de With
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

4.  Hand infections following penetrating fish fins or bones injuries (FFBI): a large, hospital based, retrospective study.

Authors:  R Imberg; I Potasman; Y Weissman; M Grupper
Journal:  Infection       Date:  2008-08-25       Impact factor: 3.553

5.  On being the right size: the impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community.

Authors:  Roger D Kouyos; Pia Abel Zur Wiesch; Sebastian Bonhoeffer
Journal:  PLoS Pathog       Date:  2011-04-14       Impact factor: 6.823

6.  Analysis of antibiotic consumption in burn patients.

Authors:  Somayeh Soleymanzadeh-Moghadam; Leila Azimi; Laleh Amani; Aida Rastegar Lari; Faranak Alinejad; Abdolaziz Rastegar Lari
Journal:  GMS Hyg Infect Control       Date:  2015-06-09

7.  Perioperative antibiotic prophylaxis in elective surgeries in Iran.

Authors:  Behzad Foroutan; Reza Foroutan
Journal:  Med J Islam Repub Iran       Date:  2014-07-15

8.  Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality.

Authors:  Ana Díaz-Martín; María Luisa Martínez-González; Ricard Ferrer; Carlos Ortiz-Leyba; Enrique Piacentini; Maria Jesus Lopez-Pueyo; Ignacio Martín-Loeches; Mitchell M Levy; Antoni Artigas; José Garnacho-Montero
Journal:  Crit Care       Date:  2012-11-18       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.